Leuven, Belgium – March 23, 2018. Materialise NV (Nasdaq: MTLS) is the first company in the world to receive FDA clearance for software intended for 3D printing anatomical models for diagnostic use. Leading hospitals are adopting integrated 3D printing services as part of their medical practices as they recognize the added value it brings to personalized patient care. Materialise brings nearly three decades of experience in developing medical solutions that help researchers, engineers and clinicians achieve the desired patient outcomes.
PLYMOUTH, Michigan – March 6, 2018. Materialise NV (Nasdaq: MTLS) launched a shoulder planner for surgeons with the possibility to plan shoulder arthroplasty cases and order patient-specific shoulder guides, in collaboration with DePuy Synthes. The TRUMATCH® Personalized Solutions Shoulder System, revealed at the AAOS Annual Meeting in New Orleans, marks a further extension of Materialise’s longstanding collaboration with DePuy Synthes, who will distribute the solution in the United States, Canada, Australia, New Zealand and Europe.
PLYMOUTH, MICH., Oct. 26, 2017 – Mitral regurgitation affects more than 4 million Americans – nearly one in 10 people aged 75 or older. Currently the primary option for the disease is open-heart surgery, which holds extremely high risks for patients in this age group and can prevent treatment in many cases. Non-invasive methods are entering the market to address this need and physicians are recognizing the importance of pre-surgical planning for this complex disease. Entering their pre-market phase of development, Materialise is working with select U.S. and EU hospital partners to validate the importance of accurate 3D modeling to help physicians plan complex transcatheter mitral valve replacement & repair (TMVR/r) procedures.